Previous close | 9.74 |
Open | 9.74 |
Bid | 9.10 x 1100 |
Ask | 11.36 x 1000 |
Day's range | 9.30 - 9.76 |
52-week range | 8.06 - 18.68 |
Volume | |
Avg. volume | 133,380 |
Market cap | 415.555M |
Beta (5Y monthly) | 0.08 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.67 |
Earnings date | 03 May 2023 - 08 May 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 27.00 |
CAMBRIDGE, Mass. & MONTREAL, March 14, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the data from the Phase I/II trials evaluating camonsertib (RP-3500/RG6526, partnered with Roche) in combination with three poly (ADP-ribose) polymerase inhibitors (PARPi) has been selected for the clinical plenary session at the 2023 AACR Annual Meeting, held April 14-19, 2023, in Orlando, Florida. An AACR assigned
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -2.74% and 84.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass. & MONTREAL, February 28, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022.